First Wave BioPharma, Inc.

Equities

FWBI

US33749P4081

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 03:05:04 2024-05-14 pm EDT			5-day change	1st Jan Change
2.93 ^USD	-2.01%		+10.98%	-30.24%

May. 10	First Wave BioPharma, Inc. announced a financing transaction	CI
Mar. 29	First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

First Wave BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 13, 2023 at 04:16 pm EST

First Wave BioPharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 3.43 million compared to net income of USD 4.39 million a year ago. Basic loss per share from continuing operations was USD 9.2 compared to basic earnings per share from continuing operations of USD 370.2 a year ago. Diluted loss per share from continuing operations was USD 9.2 compared to diluted earnings per share from continuing operations of USD 364.6 a year ago.
For the nine months, net loss was USD 11.69 million compared to USD 10.64 million a year ago. Basic loss per share from continuing operations was USD 63.4. Diluted loss per share from continuing operations was USD 63.4.

Latest news about First Wave BioPharma, Inc.

First Wave BioPharma, Inc. announced a financing transaction	May. 09	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	Mar. 14	MT
Sector Update: Health Care	Mar. 14	MT
First Wave BioPharma Shares Fall After Acquiring ImmunogenX	Mar. 14	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Inflation Data	Mar. 14	MT
First Wave Biopharma, Inc. Announces Management Changes	Mar. 14	CI
First Wave BioPharma, Inc. completed the acquisition of ImmunogenX, LLC for approximately $3 million.	Mar. 12	CI
Top Premarket Gainers	Jan. 03	MT
Wall St ticks up, S&P 500 near all-time closing high	Dec. 27	RE
Sector Update: Health Care Stocks Gain Late Afternoon	Dec. 27	MT
First Wave BioPharma Investors Exercise Warrants at Reduced Price -- Shares Up	Dec. 27	MT
Wall St wavers as S&P 500 hovers near all-time closing high	Dec. 27	RE
Sector Update: Health Care Stocks Higher Wednesday Afternoon	Dec. 27	MT
Sector Update: Health Care	Dec. 27	MT
Wall Street rises, S&P close to all-time high	Dec. 27	RE
Traders Look Ahead to Flat Day After Post-Christmas Rally	Dec. 27	MT
US Stock Market Futures Sluggish Following Holiday Gains	Dec. 27	MT
Top Midday Gainers	Dec. 27	MT
Top Premarket Gainers	Dec. 27	MT
First Wave BioPharma Shares Skyrocket After Selling Prospective Treatment for Inflammatory Bowel Diseases	Dec. 27	MT
First Wave BioPharma, Inc. signed a non-binding term sheet to acquire ImmunogenX, LLC.	Dec. 17	CI
First Wave BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
First Wave BioPharma Files for Secondary Offering of Shares	23-09-22	MT
Top Midday Gainers	23-09-14	MT

Chart First Wave BioPharma, Inc.

Duration

Period

More charts

Company Profile

First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.

Sector

Biotechnology & Medical Research

Calendar

2024-05-19 - Digestive Disease Week Conference - A Composite Mucosal Scale for Celiac Disease

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.99 USD

Average target price

36 USD

Spread / Average Target

+1,104.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FIRST WAVE BIOPHARMA, INC.	-30.24%	6.06M
MODERNA, INC.	+28.30%	48.16B
IQVIA HOLDINGS INC.	-0.16%	41.73B
LONZA GROUP AG	+43.45%	41.03B
CELLTRION, INC.	-5.26%	28.77B
ICON PUBLIC LIMITED COMPANY	+11.02%	25.59B
ALNYLAM PHARMACEUTICALS, INC.	-22.68%	18.96B
BIO-TECHNE CORPORATION	+8.63%	12.92B
MEDPACE HOLDINGS, INC.	+29.93%	12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.79%	11.77B

Other Biotechnology & Medical Research